The Use of Selective Inhibitor of If-Channels Ivabradine in Patients with Ischemic Heart Disease, Heart Failure with High Heart Rate

Ischemic heart disease (IHD) and chronic heart failure (CHF) belong to leading causes of death among patients with cardiovascular diseases (CVD). Modern medical approaches to the treatment of patients with CHF do not always provide a significant improvement in the quality of life, a decrease in the frequency of CHF exacerbations and hospitalizations, and an improvement of the long-term prognosis. According to the neurohumoral theory of IHD and CHF development, the blockade of the sympathoadrenal system with β-adrenoblockers (β-AB) is pathogenetically substantiated, and preparations of this group are recommended as one of the main classes of drugs for the treatment of patients with CHF. However, selection of heart rhythm slowing therapy in patients with CHF of ischemic genesis is often difficult due to the development of undesirable side effects of β-AB, intolerance and/or due to the presence of contraindications for their use. Randomized studies have shown that prescribing a combination of β-AB and If-channel blocker ivabradine for heart rate (HR) reduction or solely ivabradine when use of β-AB is impossible in complex CHF therapy, improves the left ventricle (LV) diastolic function, reducing mortality from CHF decompensation. However, the prognostic significance of the use of ivabradine in patients with CHF with preserved left ventricular ejection fraction of ischemic genesis with heart rate higher than 70 beats/min receiving maximum tolerated doses of β-AB remains not fully investigated.

1. Kenworthy W, Guha K, Sharma R. The patient with left ventricular systolic dysfunction now and in the future. British Journal of Hospital Medicine. 2016;77(9):516-22. DOI: 10.12968/hmed.2016.77.9.516

2. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137-46. DOI: 10.1136/hrt.2003.025270

3. Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289(2):194-202. PMID: 12517230

4. Bleumink GS, Knetsch AM, Sturkenboom MCJM, Straus SMJM, Hofman A, Deckers JW et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. European Heart Journal. 2004;25(18):1614-9. DOI: 10.1016/j.ehj.2004.06.038

5. Ceia F, Fonseca C, Mota T, Morais H, Matias F, de Sousa A et al. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. European Journal of Heart Failure. 2002;4(4):531-9. DOI: 10.1016/S1388-9842(02)00034-X

6. Fomin I.V. Chronic heart failure in Russian Federation: what do we know and what to do. Russian journal of cardiology. 2016;8:7-13. DOI: 10.15829/1560-4071-2016-8-7-13

7. Ageev F.T., Danielyan M.O., Mareev V.Yu., Belenkov Yu.N. Patients with chronic heart failure in the Russian ambulatory practice: contingent features, diagnosis and treatment (studies ofAGE-O-CHF). Russian Heart Failure Journal. 2004;5(1):4-7.

8. Mareev VYu., Danielyan M.O., Belenkov Yu.N. Comparative characteristics of patients with CHF in relation to the value of injection fraction by data from the Russian multicenter study EPOCH-A-CHF: once more about the problem of CHF with preserved left ventricular systolic function. Russian Heart Failure Journal. 2006;7(4):164-71.

9. Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). European Journal of Heart Failure. 2013;15(7):808-17. DOI: 10.1093/eurjhf/hft050

10. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016;133(4):e38-360. DOI: 10.1161/CIR.0000000000000350

11. National Institute for Health and Care Excellence. Chronic heart failure in adults: management. [Internet] 2010. Available at: https://www.nice.org.uk/guidance/cg108

12. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129-200. DOI: 10.1093/eurheartj/ehw128

13. Cook S, Togni M, Schaub MC, Wenaweser P, Hess OM. High heart rate: a cardiovascular risk factor? European Heart Journal. 2006;27(20):2387-93. DOI: 10.1093/eurheartj/ehl259

14. Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL et al. Resting heart rate in cardiovascular disease. Journal of the American College of Cardiology. 2007;50(9):823-30. DOI: 10.1016/j.jacc.2007.04.079

15. Reil J-C, Bohm M. The role of heart rate in the development of cardiovascular disease. Clinical Research in Cardiology. 2007;96(9):585-92. DOI: 10.1007/s00392-007-0537-5

16. Giannoglou GD, Chatzizisis YS, Zamboulis C, Parcharidis GE, Mikhailidis DP, Louridas GE. Elevated heart rate and atherosclerosis: An overview of the pathogenetic mechanisms. International Journal of Cardiology. 2008;126(3):302-12. DOI: 10.1016/j.ijcard.2007.08.077

17. Custodis F, Schirmer SH, Baumhakel M, Heusch G, Bohm M, Laufs U. Vascular Pathophysiology in Response to Increased Heart Rate. Journal of the American College of Cardiology. 2010;56(24):1973-83. DOI: 10.1016/j.jacc.2010.09.014

18. Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. British Journal of Pharmacology. 2008;153(8):1589-601. DOI: 10.1038/sj.bjp.0707673

19. Monnet X, Ghaleh B, Colin P, de Curzon OP, Giudicelli JF, Berdeaux A. Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning. The Journal of Pharmacology and Experimental Therapeutics. 2001;299(3):1133-9. PMID: 11714904

20. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. Journal of the American College of Cardiology. 1995;26(5):1257-63. DOI: 10.1016/0735-1097(95)00332-0

21. Mengesha HG, Weldearegawi B, Petrucka P, Bekele T, Otieno MG, Hailu A. Effect of ivabradine on cardiovascular outcomes in patients with stable angina: meta-analysis of randomized clinical trials. BMC Cardiovascular Disorders. 2017;17(1):105. DOI: 10.1186/s12872-017-0540-3

22. Greene SJ, Vaduganathan M, Wilcox JE, Harinstein ME, Maggioni AP, Subacius H et al. The Prognostic Significance of Heart Rate in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in Sinus Rhythm. JACC: Heart Failure. 2013;1(6):488-96. DOI: 10.1016/j.jchf.2013.08.005

23. Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz A, Werhlen-Grandjean M et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation. 2001;103(10):1428-33. PMID: 11245648

24. Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of Randomized Controlled Trials on the Effect of Magnitude of Heart Rate Reduction on Clinical Outcomes in Patients With Systolic Chronic Heart Failure Receiving Beta-Blockers. The American Journal of Cardiology. 2008; 101 (6):865-9. DOI: 10.1016/j.amjcard.2007.11.023

25. McAlister FA. Meta-analysis: p-blocker dose, heart rate reduction, and death in patients with heart failure. Annals of Internal Medicine. 2009;150(11):784-94. DOI: 10.7326/0003-4819-150-11-200906020-00006

26. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. The Lancet. 2008;372(9641):807-16. DOI: 10.1016/S0140-6736(08)61170-8

27. Tardif J-C, Ponikowski P, Kahan T. Effects of ivabradine in patients with stable angina receiving beta-blockers according to baseline heart rate: an analysis of the ASSOCIATE study. International Journal of Cardiology. 2013;168(2):789-94. DOI: 10.1016/j.ijcard.2012.10.011

28. Dillinger J-G, Maher V, Vitale C, Henry P, Logeart D, Manzo Silberman S et al. Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease. Hypertension. 2015;66(6):1138-44. DOI: 10.1161/HYPERTENSIONAHA.115.06091

29. Skalidis EI, Hamilos MI, Chlouverakis G, Zacharis EA, Vardas PE. Ivabradine improves coronary flow reserve in patients with stable coronary artery disease. Atherosclerosis. 2011;215(1):160-5. DOI: 10.1016/j.atherosclerosis.2010.11.035

30. Gloekler S, Traupe T, Stoller M, Schild D, Steck H, Khattab A et al. The effect of heart rate reduction by ivabradine on collateral function in patients with chronic stable coronary artery disease. Heart. 2014;100(2):160-6. DOI: 10.1136/heartjnl-2013-304880

31. Custodis F, Baumhakel M, Schlimmer N, List F, Gensch C, Bohm M et al. Heart Rate Reduction by Ivabradine Reduces Oxidative Stress, Improves Endothelial Function, and Prevents Atherosclerosis in Apolipoprotein E-Deficient Mice. Circulation. 2008;117(18):2377-87. DOI: 10.1161/CIRCULATIO-NAHA.107.746537

32. Schirmer SH, Degen A, Baumhakel M, Custodis F, Schuh L, Kohlhaas M et al. Heart-rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis. European Heart Journal. 2012;33(10):1223-31. DOI: 10.1093/eurheartj/ehr255

33. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. The Lancet. 2010;376(9744):875-85. DOI: 10.1016/S0140-6736(10)61198-1

34. Volterrani M, Cice G, Caminiti G, Vitale C, D'Isa S, Perrone Filardi P et al. Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). International Journal of Cardiology. 2011;151(2):218-24. DOI: 10.1016/j.ijcard.2011.06.098

35. Dierckx R, Cleland JGF, Parsons S, Putzu P, Pellicori P, Dicken B et al. Prescribing Patterns to Optimize Heart Rate: analysis of 1,000 consecutive outpatient appointments to a single heart failure clinic over a 6-month period. JACC: Heart Failure. 2015;3(3):224-30. DOI: 10.1016/j.jchf.2014.11.003

36. Komajda M, Isnard R, Cohen-Solal A, Metra M, Pieske B, Ponikowski P et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial: Ivabradine in HFpEF. European Journal of Heart Failure. 2017;19(11):1495-503. DOI: 10.1002/ejhf.876